EGFR and non-small cell lung carcinoma: CHRYSALIS-2 (64) is an ongoing phase 1/1b open-label study evaluating the effects of amivantamab + lazertinib in patients with EGFR-mutant NSCLC (first-line therapy) and a phase 3 study (MARIPOSA) in ongoing to assess activity of the combination in EGFR-mutant NSCLC (first-line therapy) (65).